Giannitrapani K, Fereydooni S, Azarfar A, et al. - Researchers sought to ascertain the perspectives of patients and providers on using signature informed consent (SIC) for long-term opioid therapy (LTOT) in patients with cancer-related pain. They conducted semi-structured interviews with 20 opioid prescribers and 20 patients who were prescribed opioids. SIC is related to advantages like its potential for clarifying and helping patients comprehend LTOT risks and benefits, providing clear upfront boundaries and expectations, and involving the patient in shared decision-making. Potential disadvantages related to SIC are it may lead to time delay to treatment, discouragement from recommended opioid use, and impaired trust in the patient-provider relationship. Misconceptions regarding the definition of SIC were identified among providers and patients. Findings emphasize the following as important considerations: tailoring SIC for LTOT to be specific to cancer-related concerns and to have an appropriate literacy level.